TOMI Environmental Solutions, Inc. TOMZ

Company Overview

TOMI Environmental Solutions, Inc. (NYSE American: TOMZ) is a U.S.-based environmental services and infection prevention company focused on disinfection, decontamination, and infectious disease control technologies. The company operates primarily in the healthcare, life sciences, biotechnology, pharmaceutical, food safety, defense, and commercial facility markets. Its core platform is the proprietary SteraMist system, which uses ionized hydrogen peroxide (iHP) technology to deliver surface and airborne disinfection in enclosed environments. Revenue is generated through equipment sales, recurring consumable products, service contracts, training, and validation services.

The company traces its origins to research and commercialization efforts surrounding binary ionization technology and advanced hydrogen peroxide disinfection systems. Over time, TOMI evolved from a specialty environmental solutions provider into a company focused on high-level decontamination applications for regulated industries and critical infrastructure. Its strategic positioning centers on offering lower-residue, rapid-cycle decontamination technology designed for environments where contamination control and regulatory compliance are operational priorities.

Business Operations

TOMI conducts business through the commercialization and servicing of its SteraMist product family, which includes room environment systems, transportable handheld units, integrated chamber systems, and customized decontamination solutions. The company’s operations include equipment manufacturing oversight, consumable distribution, field service support, validation consulting, and customer training. Its primary revenue drivers are product sales and recurring purchases of hydrogen peroxide-based consumables used within the SteraMist ecosystem.

The company operates domestically in the United States and internationally through distributors, channel partners, and direct customer relationships across healthcare, pharmaceutical manufacturing, research laboratories, and government sectors. TOMI has established relationships with hospitals, cleanroom operators, universities, biosafety laboratories, and defense-related organizations. The company’s intellectual property portfolio and proprietary iHP application process represent key operational assets supporting its competitive positioning in the decontamination market.

Strategic Position & Investments

TOMI’s strategic direction has focused on expanding adoption of its SteraMist technology in regulated and contamination-sensitive industries, particularly pharmaceutical manufacturing, life sciences, and healthcare infrastructure. The company has pursued growth through expanded distributor networks, international market penetration, and broader use cases for iHP technology in biosafety and infection prevention. Public disclosures indicate ongoing investment in product development, regulatory compliance capabilities, and commercial partnerships intended to increase recurring revenue opportunities tied to consumables and service offerings.

The company has also emphasized applications involving cleanroom decontamination, biodefense preparedness, and high-containment laboratory environments. TOMI’s technology gained broader visibility during periods of elevated infection-control demand, including healthcare and public health response environments. Data regarding major acquisitions or extensive portfolio holdings is inconclusive based on available public sources, as TOMI primarily appears to operate as a focused technology and services company rather than a diversified holding organization.

Geographic Footprint

TOMI is headquartered in California, United States, and serves customers across North America, Europe, Asia-Pacific, the Middle East, and parts of Latin America through a combination of direct operations and international distribution partners. Its international presence has historically centered on regulated industries requiring advanced disinfection protocols, including pharmaceutical production, laboratory research, and healthcare facilities.

The company’s global operational influence is tied more to technology deployment and distributor relationships than to large-scale international manufacturing infrastructure. Public filings and corporate disclosures indicate that international sales have represented an important component of growth strategy, particularly in regions with expanding cleanroom, healthcare, and biosafety investments.

Leadership & Governance

TOMI’s leadership has emphasized technology-driven infection prevention, regulatory compliance, and expansion into mission-critical decontamination markets. Corporate governance and strategic direction have largely focused on commercializing the company’s proprietary iHP technology platform while strengthening recurring revenue streams and international market access.

Key executives and leadership figures publicly associated with the company include:

• Dr. Halden Shane – Chief Executive Officer and Chairman
• Nick Jennings – Chief Operating Officer
• Ron Fink – Vice President of Sales

Additional executive and governance information may vary across reporting periods and public disclosures. Data regarding certain executive appointments or tenure changes is inconclusive based on available public sources.